88 related articles for article (PubMed ID: 38389832)
1. Development of CD46 targeted alpha theranostics in prostate cancer using
Bobba KN; Bidkar AP; Wadhwa A; Meher N; Drona S; Sorlin AM; Bidlingmaier S; Zhang L; Wilson DM; Chan E; Greenland NY; Aggarwal R; VanBrocklin HF; He J; Chou J; Seo Y; Liu B; Flavell RR
Theranostics; 2024; 14(4):1344-1360. PubMed ID: 38389832
[No Abstract] [Full Text] [Related]
2. CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma.
Wadhwa A; Wang S; Patiño-Escobar B; Bidkar AP; Bobba KN; Chan E; Meher N; Bidlingmaier S; Su Y; Dhrona S; Geng H; Sarin V; VanBrocklin HF; Wilson DM; He J; Zhang L; Steri V; Wong SW; Martin TG; Seo Y; Liu B; Wiita AP; Flavell RR
Clin Cancer Res; 2024 Mar; 30(5):1009-1021. PubMed ID: 38109209
[TBL] [Abstract][Full Text] [Related]
3. Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer.
Schatz CA; Zitzmann-Kolbe S; Moen I; Klotz M; Nair S; Stargard S; Bjerke RM; Wickstrøm Biseth K; Feng YZ; Indrevoll B; Cruciani V; Karlsson J; Haendler B; Nielsen CH; Alfsen MZ; Hammer S; Hennekes H; Cuthbertson A; Hagemann UB; Larsen A
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38593212
[TBL] [Abstract][Full Text] [Related]
4. Towards Targeted Alpha Therapy with Actinium-225: Chelators for Mild Condition Radiolabeling and Targeting PSMA-A Proof of Concept Study.
Reissig F; Bauer D; Zarschler K; Novy Z; Bendova K; Ludik MC; Kopka K; Pietzsch HJ; Petrik M; Mamat C
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33923965
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of HER2-Targeted Intraperitoneal
Chung SK; Vargas DB; Chandler CS; Katugampola S; Veach DR; McDevitt MR; Seo SH; Vaughn BA; Rinne SS; Punzalan B; Patel M; Xu H; Guo HF; Zanzonico PB; Monette S; Yang G; Ouerfelli O; Nash GM; Cercek A; Fung EK; Howell RW; Larson SM; Cheal SM; Cheung NV
J Nucl Med; 2023 Sep; 64(9):1439-1445. PubMed ID: 37348919
[TBL] [Abstract][Full Text] [Related]
6. First In Vivo and Phantom Imaging of Cyclotron-Produced
Nelson BJB; Ferguson S; Wuest M; Wilson J; Duke MJM; Richter S; Soenke-Jans H; Andersson JD; Juengling F; Wuest F
J Nucl Med; 2022 Apr; 63(4):584-590. PubMed ID: 34385334
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of an alpha-particle emitter labeled anti-GD2 humanized antibody against osteosarcoma-a proof of concept study.
Liatsou I; Fu Y; Li Z; Hasan M; Guo X; Yu J; Piccolo J; Cartee A; Wang H; Du Y; Bryan J; Gabrielson K; Kraitchman DL; Sgouros G
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1409-1420. PubMed ID: 38108831
[TBL] [Abstract][Full Text] [Related]
8. Albumin-Binding Lutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma.
Pun MD; Gallazzi F; Ho KV; Watkinson L; Carmack TL; Iweha E; Li L; Anderson CJ
Mol Pharm; 2024 Apr; ():. PubMed ID: 38680059
[TBL] [Abstract][Full Text] [Related]
9. Recent Insights in Barium-131 as a Diagnostic Match for Radium-223: Cyclotron Production, Separation, Radiolabeling, and Imaging.
Reissig F; Bauer D; Ullrich M; Kreller M; Pietzsch J; Mamat C; Kopka K; Pietzsch HJ; Walther M
Pharmaceuticals (Basel); 2020 Sep; 13(10):. PubMed ID: 32992909
[TBL] [Abstract][Full Text] [Related]
10. Astatine-211 Radiopharmaceuticals; Status, Trends, and the Future.
Rabiei M; Asadi M; Yousefnia H
Curr Radiopharm; 2024; 17(1):7-13. PubMed ID: 37937552
[TBL] [Abstract][Full Text] [Related]
11. Combined, yet separate: cocktails of carriers (not drugs) for actinium-225 α-particle therapy of solid tumors expressing moderate-to-low levels of targetable markers.
Nair RR; Prasad A; Bhatavdekar O; Sarkar A; Gabrielson KL; Sofou S
Eur J Nucl Med Mol Imaging; 2024 Apr; ():. PubMed ID: 38641714
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts.
Gerber DE; Hao G; Watkins L; Stafford JH; Anderson J; Holbein B; Öz OK; Mathews D; Thorpe PE; Hassan G; Kumar A; Brekken RA; Sun X
Am J Nucl Med Mol Imaging; 2015; 5(5):493-503. PubMed ID: 26550540
[TBL] [Abstract][Full Text] [Related]
13. Ac-EAZY! Towards GMP-Compliant Module Syntheses of
Pretze M; Kunkel F; Runge R; Freudenberg R; Braune A; Hartmann H; Schwarz U; Brogsitter C; Kotzerke J
Pharmaceuticals (Basel); 2021 Jul; 14(7):. PubMed ID: 34358076
[TBL] [Abstract][Full Text] [Related]
14. Conjugation of Antibodies with Radiogold Nanoparticles, as an Effector Targeting Agents in Radiobioconjugate Cancer Therapy: Optimized Labeling and Biodistribution Results.
Garg P; Hazra DK
Indian J Nucl Med; 2017; 32(4):296-303. PubMed ID: 29142346
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in nanoscale materials for antibody-based cancer theranostics.
Kukkar D; Kukkar P; Kumar V; Hong J; Kim KH; Deep A
Biosens Bioelectron; 2021 Feb; 173():112787. PubMed ID: 33190049
[TBL] [Abstract][Full Text] [Related]
16. Cyanine conjugates in cancer theranostics.
Li Y; Zhou Y; Yue X; Dai Z
Bioact Mater; 2021 Mar; 6(3):794-809. PubMed ID: 33024900
[TBL] [Abstract][Full Text] [Related]
17. Actinium-225 targeted alpha particle therapy for prostate cancer.
Bidkar AP; Zerefa L; Yadav S; VanBrocklin HF; Flavell RR
Theranostics; 2024; 14(7):2969-2992. PubMed ID: 38773983
[TBL] [Abstract][Full Text] [Related]
18. Exploring the PET in vivo generator
Bauer D; De Gregorio R; Pratt EC; Bell A; Michel A; Lewis JS
bioRxiv; 2024 Apr; ():. PubMed ID: 38712285
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
